Direct Answer
Protagonist Therapeutics is a clinical-stage biopharmaceutical company whose lead asset, rusfertide, is a subcutaneous hepcidin mimetic under FDA review for polycythemia vera (PV), a rare blood cancer characterized by excess red blood cell production. Protagonist has a partnership with Johnson and Johnson for rusfertide's commercial development. Revenue depends on NDA approval, successful commercial launch and royalties under the JNJ deal.
What Protagonist Therapeutics Does
Protagonist is focused on developing peptide-based medicines for blood disorders and inflammatory conditions. Hepcidin, a hormone produced by the liver, regulates iron absorption by degrading ferroportin on cells responsible for iron export. In polycythemia vera, the JAK2 mutation drives uncontrolled red blood cell production; elevated red cell counts require therapeutic phlebotomy (blood removal) to reduce hematocrit, which also depletes iron and worsens iron deficiency.
Rusfertide mimics hepcidin, reducing iron availability to erythroid progenitors and thereby suppressing excess red blood cell production without depleting iron stores. In the Phase 3 REVIVE trial, rusfertide significantly reduced phlebotomy procedures versus placebo in patients with PV who were on cytoreductive therapy or phlebotomy alone. The NDA was filed with the FDA in 2025.
A second program, PN-943 (now partnered with JNJ as JNJ-2113 and also referred to as icotrokinra), targets the IL-23 pathway for inflammatory bowel disease (IBD), specifically ulcerative colitis. This is a larger market than PV with numerous competitors but also a substantially larger revenue potential if approved.
Business Model and Revenue Sources
Protagonist is pre-commercial and generates revenue from its collaboration agreement with Janssen Pharmaceutica (Johnson and Johnson subsidiary). The agreement provides for milestone payments upon regulatory and commercial achievements and a royalty on net sales for products developed under the collaboration.
Protagonist retains co-promotion rights for rusfertide in the United States at launch, which means the company will contribute a dedicated sales force for the PV indication and share in commercialization economics. For JNJ-2113 (the IL-23/IBD program), Protagonist receives royalties without independent commercialization responsibility.
The business model is binary relative to the NDA outcome. If rusfertide is approved, Protagonist transitions to a commercial-stage company with PV revenue and royalties from JNJ-2113 as a potential second stream. If the FDA requires additional data or issues a complete response letter, Protagonist must raise capital or delay commercial assumptions substantially.
Key Milestones and Metrics to Track
| Milestone/Metric | Why It Matters |
|---|---|
| FDA PDUFA action date for rusfertide NDA | Binary approval event; primary near-term catalyst |
| REVIVE trial complete response (any additional FDA questions) | Signal of approval path |
| JNJ-2113 (icotrokinra) Phase 3 data readouts in UC | Second revenue stream potential via royalties |
| Cash runway | Pre-revenue company must fund operations until milestone payments or launch |
| PV diagnosis incidence (approximately 22 per 100,000 in U.S.) | Addressable patient population for commercial planning |
Competitive Position
In polycythemia vera, standard of care has been hydroxyurea (a cytoreductive agent with long-term toxicity concerns) and ruxolitinib (Jakafi, a JAK1/2 inhibitor indicated for patients inadequately controlled on hydroxyurea). Neither agent directly targets hepcidin, and phlebotomy remains the primary tool for hematocrit control. Rusfertide would be the first hepcidin mimetic in this indication, representing a mechanistically distinct option.
The competitive moat in PV is the mechanistic novelty and the REVIVE data. If approved, rusfertide would be the only approved hepcidin mimetic for PV and would likely be positioned for patients who need phlebotomy reduction without the cytoreduction of hydroxyurea or ruxolitinib, or as an add-on to existing cytoreductive therapy.
PV is an orphan-eligible indication with limited prescriber universe (mostly hematologists/oncologists), which has implications for sales force sizing and market access negotiations. Small addressable patient populations require high drug pricing and efficient commercial execution.
Principal Risks
- FDA regulatory risk: A complete response letter requesting additional data would delay approval and require additional capital. The FDA may have questions about manufacturing, labeling or risk mitigation beyond the Phase 3 data.
- Commercial execution risk: Even if approved, penetrating the hematology-oncology prescriber base requires building relationships with a specialized physician universe, which takes time and investment.
- Single-asset concentration: Rusfertide in PV is the company's near-term commercial bet. Any regulatory setback concentrates risk entirely on the JNJ royalty stream from JNJ-2113.
- Competition from next-generation PV therapies: Novel JAK inhibitors and other pipeline agents targeting PV are in development and could dilute the available patient pool for rusfertide.
- Cash and capital needs: Pre-revenue companies must fund commercial build-out ahead of launch revenue. Protagonist will need capital to fund its co-promotion obligation.
What to Monitor
- FDA PDUFA date and any agency communication about the rusfertide NDA
- JNJ-2113 Phase 3 ulcerative colitis trial data (readout expected 2025-2026)
- Cash position and any capital raises or milestone receipt
- Management guidance on commercial infrastructure build-out ahead of anticipated approval
- Any updated clinical data presentations at medical conferences (ASH, EHA) on rusfertide
FAQ
What is polycythemia vera?
Polycythemia vera (PV) is a rare myeloproliferative neoplasm (blood cancer) caused by an acquired mutation in the JAK2 gene that drives excess production of red blood cells, and often platelets and white blood cells. Elevated red cell counts increase blood viscosity, raising the risk of blood clots (stroke, heart attack, deep vein thrombosis). Treatment aims to keep hematocrit below 45% through phlebotomy, hydroxyurea or JAK inhibitors. Prevalence is approximately 22 per 100,000 in the United States.
What is the Johnson and Johnson partnership?
Protagonist partnered with Janssen (JNJ's pharmaceutical subsidiary) for both rusfertide in PV and the JNJ-2113 (icotrokinra/PN-943) program in IBD. JNJ paid upfront and milestone payments and is responsible for global commercial development of JNJ-2113, with Protagonist receiving royalties on net sales. For rusfertide in the U.S., Protagonist retains co-promotion rights, contributing a sales force and sharing in commercial economics. The partnership provides financial support but Protagonist's equity value is substantially tied to royalty and co-promotion economics.
What is hepcidin and why does it matter for PV treatment?
Hepcidin is a liver-produced hormone that regulates iron absorption by targeting ferroportin, an iron-export protein. When hepcidin binds ferroportin, cells retain iron rather than releasing it into the bloodstream, reducing iron available for red blood cell production. In PV, where excess red blood cells are the disease driver, rusfertide's hepcidin mimicry reduces iron availability to erythroid progenitors, suppressing overproduction without the systemic toxicity of chemotherapy-class cytoreductive agents.
What is JNJ-2113 and what is its market potential?
JNJ-2113 (icotrokinra) is a subcutaneous peptide IL-23 receptor antagonist in Phase 3 trials for ulcerative colitis and psoriasis. Ulcerative colitis is a much larger market than PV, with multiple approved biologics including anti-TNF agents, anti-integrin therapies and other IL-23 antagonists. If JNJ-2113 demonstrates differentiated efficacy (potentially as a subcutaneous peptide vs. injectable monoclonal antibodies), the royalty stream for Protagonist could be material. Phase 3 data readouts are the primary catalyst for this program.
How should investors think about valuation for a pre-commercial biotech?
Pre-commercial biotechs like Protagonist are typically valued through probability-adjusted net present value (NPV) models. Investors assign an approval probability to the lead asset, model peak sales in the addressable indication, apply a royalty or commercial-stage margin assumption, discount back to present value, and risk-adjust by the phase and regulatory status. Binary approval events cause significant stock price moves in both directions, so position sizing should reflect the binary-outcome risk rather than treating the stock as a steady-state investment.
References
- Protagonist Therapeutics Inc. SEC filings (10-K, 10-Q) via SEC EDGAR
- FDA: Rare disease resources and orphan drug designations
- REVIVE Phase 3 trial registration (ClinicalTrials.gov NCT04057040)